Disco Pharmaceuticals

Executive Summary

Disco Pharmaceuticals is a Berlin-based biotech founded in 2021, leveraging a proprietary cell surfaceome discovery platform to identify novel surface-bound proteins and protein communities on cancer cells. The company aims to expand the druggable target universe, focusing on developing first-in-class antibody therapies for high unmet need cancers such as Small Cell Lung Cancer (SCLC) and microsatellite-stable Colorectal Cancer (MSS CRC). By targeting the cell surface proteome, Disco’s approach enables the identification of both single targets and target communities, potentially leading to more effective and less resistance-prone therapies. The company has assembled a strong scientific team and is backed by initial seed funding, though financial details remain undisclosed. Since its founding, Disco has been advancing its lead programs toward preclinical candidate nomination. The platform’s ability to systematically map the surfaceome of tumors positions it to generate a robust pipeline of antibody candidates. While still at an early stage, the company has not yet disclosed specific development timelines or regulatory interactions. The key near-term value inflection points include completion of in vivo proof-of-concept studies, securing Series A financing to fund IND-enabling activities, and potential out-licensing or co-development partnerships with larger pharma. Given the high unmet need in SCLC and MSS CRC and the novelty of the platform, Disco represents an attractive early-stage opportunity in precision oncology, though execution risk remains considerable.

Upcoming Catalysts (preview)

• Q3 2026In vivo proof-of-concept data for lead antibody program50% success
• Q4 2026Series A financing round60% success
• Q1 2027Partnership or co-development deal for platform or lead program40% success